STERIS stock
STENYSESTERIS plc, HealthcareISIN IE00BFY8C754
70Score 70 out of 100, Strong
Price and trend
69 / 100
Price history
−3.9% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 74).
The price is 4.6% below its 52-week high. Largest decline in 20 years: 50% (September 2008 to March 2009).
Chart figures for advanced users
- SMA 50$222.06
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$224.16
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)74
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$199.40
- The lowest closing price of the last twelve months.
- Resistance$268.65
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- STERIS plc belongs to the Medical (Specialties) industry (United States) and, with a market value of $24.89B, is number 2 of 14 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $5.94B (up 8.7% year on year) and earnings of $785.1M (up 27.7%).
- For fiscal 2027, analysts expect on average revenue of $6.38B (up 7.4%) and adjusted earnings per share of $11.21 (up 10.3%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 147 of 714 in Healthcare, median 53.
- The P/E is 30.3 (Healthcare sector median 26.7, own median of recent years 38.6).
- Our model puts fair value at $215.91, with the price 19% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 21 years.Capital allocation 50
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 86
- Earnings turn into cashFree cash flow 113% of earnings over the last 12 months.Fundamentals 86
Weaknesses
- DilutionShare count up 15% since 2021.Capital allocation 50
Its standout strengths are stability and fundamentals, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $166.08 and expensive above $308.44 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $205.43 (cash-flow model) and $226.38 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $198.35, at 7.8% it would be $242.26.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (26.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8.1% on the twelve months before. Revenue has grown solidly since 2007, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 44%, operating 19%, net 13%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 4 Nov 2026EPS reported $2.94 (expected $2.68)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $11.21+0.1%
- Revenue
- $6.38B0.0%
- Earnings per share
- $12.26+0.1%
- Revenue
- $6.78B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +2.0%Fiscal 2027 outlook maintained: EPS unchanged at $11.10 to $11.30; capex raised to about $450 million, free cash flow about $800 million.
“Our fiscal 2027 earnings per share outlook is also unchanged at $11.10-$11.30, growth of 9%-11% over fiscal 2026. While the total cost of the North Carolina facility is anticipated to be $600 million, the impact on fiscal 2027 is expected to be approximately $75 million in additional capital spending.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $2.51M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at STERIS
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next larger and next smaller companies by market value
- AlconALC.SW $34.65B62
- Shanghai United Imaging Healthcare688271.SS $14.35B53
- Sysmex6869.T $7.83B70
- Ypsomed HoldingYPSN.SW $6.56B76
- Medacta GroupMOVE.SW $2.64B58
- Eckert & ZieglerEUZ.DE $969.93M74
- QuidelOrthoQDEL $817.18M32
- Mesa LaboratoriesMLAB $782.43M58
ETFs that hold STERIS
Held by 124 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 1.22% | 0.18% | €837.43M |
| State Street SPDR S&P U.S. Dividend Aristocrats UCITS ETF (Dist)SPYD | 0.65% | 0.35% | €3.62B |
| UBS Factor MSCI USA Low Volatility UCITS ETF USD disUBUR | 0.61% | 0.18% | €64.75M |
Show 5 more
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.39% | 0.20% | €268.74M |
| UBS Factor MSCI USA Prime Value Screened UCITS ETF hEUR accUBUW | 0.38% | 0.28% | €127.84M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.37% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.35% | 0.15% | €3.27B |
| UBS Factor MSCI USA Quality Screened UCITS ETF hEUR accUBUX | 0.35% | 0.28% | €1.14B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.